NanoViricides, Inc. (NASDAQ:NNVC)

BRIEF

published on 05/16/2025 at 12:35, 11 months 16 days ago

NanoViricides Advances Antiviral NV-387 in Phase II Trials

Phase II Trial Financial Update Broad-spectrum Antiviral MPOX Treatment Measles Outbreak
PRESS RELEASE

published on 05/16/2025 at 12:30, 11 months 16 days ago

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
NanoViricides, Inc. reports filing Form 10-Q for quarter ending March 31, 2025 with SEC. Clears Phase II trial for NV-387 drug to treat MPox disease & explores Measles and Bird Flu treatments. Company has strong financials

NanoViricides NV-387 Financials Form 10-Q Phase II Trial
BRIEF

published on 05/14/2025 at 12:35, 11 months 18 days ago

NanoViricides Advances with Broad-Spectrum Antiviral Drug NV-387

Antiviral Drugs MPOX Treatment Measles Outbreak NV-387 Development Global Health Strategy
PRESS RELEASE

published on 05/14/2025 at 12:30, 11 months 18 days ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
NanoViricides, Inc. explains its drug strategy for combating viral infections and pandemics, focusing on development of antiviral nanomedicine drugs like NV-387

NanoViricides NV-387 Antiviral Nanomedicine Viral Infections
BRIEF

published on 05/08/2025 at 12:35, 11 months 24 days ago

Approval for NanoViricides' NV-387 Phase II Clinical Trial in DRC

NV-387 Clinical Trial Antiviral Drug Mpox Democratic Republic Of Congo
PRESS RELEASE

published on 05/08/2025 at 12:30, 11 months 24 days ago

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
NanoViricides, Inc. receives approval from CNES for Phase II clinical trial of NV-387 in DRC for MPox disease treatment. CEO highlights drug's broad-spectrum antiviral capabilities

NanoViricides, CNES Approval, Phase II Clinical Trial, NV-387, MPox Disease
BRIEF

published on 04/29/2025 at 12:35, 1 year ago

Potential Breakthrough in Measles Treatment: NanoViricides Develops Antiviral Drug

NanoViricides NV-387 Antiviral Drug Measles Treatment Endemic Disease
PRESS RELEASE

published on 04/29/2025 at 12:30, 1 year ago

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
NanoViricides, Inc. provides details on its Measles drug development program targeting the endemic potential of the virus in the USA and the effectiveness of their broad-spectrum antiviral drug NV-387

NV-387 NanoViricides Inc. Broad-spectrum Antiviral Measles Drug Development Vaccination Decline
BRIEF

published on 04/14/2025 at 12:35, 1 year ago

Growing Measles Threat Spurs NanoViricides to Test Antiviral Solution

Measles Outbreak NanoViricides NV-387 Antiviral Solution Viral Spread FDA Emergency Access
PRESS RELEASE

published on 04/14/2025 at 12:30, 1 year ago

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
NanoViricides, Inc. commences evaluation of clinical drug NV-387 for Measles virus treatment, utilizing innovative nanomedicine technology. Company aims to combat Measles outbreak and provide effective antiviral solution

NanoViricides NV-387 Antiviral Nanomedicine Measles

Published on 05/01/2026 at 14:00, 16 minutes ago

CCL Industries Closing of ALT Technologies Acquisition
Published on 05/01/2026 at 14:00, 16 minutes ago

Datavault AI and CyberCatch Announce Signing of Binding Letter of Intent for Datavault AI to Acquire CyberCatch to Accelerate AI-Driven, Quantum-Resistant Cyber Risk Mitigation Solutions
Published on 05/01/2026 at 13:01, 1 hour 15 minutes ago

BeMetals Announces Resumption of Trading on TSX Venture Exchange and Effective Date of Share Consolidation
Published on 05/01/2026 at 13:00, 1 hour 16 minutes ago

Abasca Resources to Participate in Core Days 2026 and Closes $2.5 Million Private Placement
Published on 05/01/2026 at 07:35, 6 hours 41 minutes ago

Snipp Interactive Reports Financial Results for Q4 and Fiscal 2025; Announces Conference Call on May 5, 2026

View all ACCESSWIRE

Published on 05/01/2026 at 14:05, 10 minutes ago

International Jazz Day 2026 Worldwide Celebration Concludes with Thrilling All-Star Global Concert from Chicago
Published on 05/01/2026 at 14:00, 16 minutes ago

Nebius Group announces date of first quarter 2026 results and conference call
Published on 05/01/2026 at 13:50, 25 minutes ago

Curaleaf Announces Appointment of Torsten Greif to Board of Directors
Published on 05/01/2026 at 13:25, 50 minutes ago

Nebius agrees to acquire Eigen AI, strengthening Nebius Token Factory as a frontier inference platform
Published on 05/01/2026 at 11:29, 2 hours 46 minutes ago

Linde Reports First-Quarter 2026 Results (Earnings Release Tables Attached)

View all EQS

Published on 04/30/2026 at 20:00, 18 hours 15 minutes ago

AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 19 hours ago

AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 19 hours 16 minutes ago

Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 20 hours 6 minutes ago

Minutes of the Combined General Meeting held on April 30, 2026
Published on 04/30/2026 at 18:00, 20 hours 15 minutes ago

TF1 Q1 2026 results - Press release

View all LES ECHOS COMFI WIRE

News